Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset CNMD

Coverage 167,604 Raw stories ingested 22,066 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,793 Assets with fetched stories

Cryptocurrencies BTC 7,377 ETH 4,877 XRP 3,296 SOL 3,014 HYPE 1,765 USDC 1,593

Stocks NVDA 1,800 SPCX 1,459 MU 1,335 MSFT 1,297 AAPL 1,085 TSLA 1,030

Commodities GOLD 560 SILVER 299 OIL 104 PLATINUM 14 PALLADIUM 4 COPPER 3

Forex EURUSD 505 GBPUSD 384 USDCAD 153 USDJPY 146 AUDUSD 100 USDCHF 63

2,195 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 53s ago
FMP Forex News Fetch every 5 min 4m ago
CoinGecko News Fetch every 5 min 1m ago
FIO Stock News Fetch every 10 min 4m ago
Patria Stock News Fetch every 10 min 4m ago
Editorial rewrite Rewrite every minute 1m ago
Asset sync Assets every 1 hour 33m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-08-31 10:36 10d ago Published 2026-08-28 12:36 12d ago	CONMED zvyšuje odhad EPS po silných výsledcích za čtvrtletí CONMED po poslední výsledkové zprávě za měsíc posílil o 7,1 %. Firma zároveň zvýšila celoroční odhad upraveného EPS na 4,48–4,60 USD. CNMD CONMED	FMP Stock News	78
Original source text A month has gone by since the last earnings report for Conmed (CNMD - Free Report) . Shares have added about 7.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for CONMED Corporation before we dive into how investors and analysts have reacted as of late. CONMED’s Q2 Earnings and Revenues Beat Estimates, Gross Margin ExpandsCONMEDposted adjusted earnings per share of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%. The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others. GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents. CNMD's Organic Sales Gain MomentumCNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter. At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%. Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%. CONMED's Orthopedic Revenues IncreaseOrthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions. Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair. CNMD's General Surgery Business ImprovesGeneral Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%. AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed. Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales. The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems. CONMED’s Margin AnalysisIn the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion. In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%. Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis. Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%. CNMD’s Financial PositionThe company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago. Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago. CONMED’s GuidanceCNMD has updated its outlook for 2026. For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year. Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026. The company now expects adjustedearnings per share PS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption. CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted earnings per share is expected to be between 98 cents and $1.03. How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month. VGM ScoresCurrently, Conmed has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top 20% for value investors. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Conmed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
	Saved 2026-08-17 20:38 23d ago Published 2026-08-17 16:06 23d ago	CONMED zvýšil tržby, čeká 35 centů tlaku na EPS CONMED ve 2. čtvrtletí zvýšil organické tržby o 6 %, ale v roce 2026 ho čeká 35 centů tlaku na EPS kvůli clům. Růst AirSeal zpomaluje. CNMD CONMED	FMP Stock News	78
Original source text Key Takeaways CONMED delivered 6% organic sales growth in Q2, with broad momentum across its continuing portfolio.Buffalo Filter is gaining from smoke-free OR laws, while BioBrace sees growing surgeon adoption and retention.AirSeal growth is slowing, while tariffs are expected to create a 35 cent EPS headwind in 2026. CONMED Corporation (CNMD - Free Report) is well positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The company’s long-term prospects seem good as robotic procedure volume rises, coupled with the expanding penetration of Ambulatory Surgery Centers. Improving supply-chain bottlenecks should drive top and bottom-line growth. CONMED is facing tariff headwinds that are unfavorably impacting its earnings per share (EPS) and revenue expansion. Higher operating expense investments remain a concern. Shares of this Zacks Rank #3 (Hold) company have gained 24.2% in the year-to-date period, outperforming the industry’s 5.8% increase and the S&P 500 Index’s 13.3% rise. Image Source: Zacks Investment Research CONMED, a renowned global medical products manufacturer specializing in surgical instruments and devices, has a market capitalization of $1.51 billion. The company projects 4.8% earnings growth over the next five years. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 11.30%. Factors Favoring CNMD StockCore Portfolio Is Returning to Healthy Organic Growth: CONMED delivered 6% organic sales growth in the second quarter of 2026, modestly above the high end of its previous expectation, despite reported revenues rising only 0.3% due to portfolio exits and currency. General Surgery grew 5.3% organically, while Orthopedic Surgery increased 6.8%, demonstrating broad-based momentum across the continuing portfolio. International orthopedic sales were particularly strong, rising 10.8%. Management remains confident in achieving at least 5% organic constant-currency growth in 2026, while expecting sequential improvement during the second half. This suggests that the business is likely to report healthier returns in the next couple of quarters as CONMED completes its portfolio optimization. Buffalo Filter Benefits From Regulatory Tailwinds: Buffalo Filter offers CONMED a potentially durable growth opportunity as surgical smoke evacuation gains regulatory momentum. Direct smoke evacuation sales exceeded the company's longer-term high-single-digit to low-double-digit growth target in the second quarter, more than offsetting declines in the OEM portfolio. Importantly, 22 U.S. states now have smoke-free operating-room laws covering approximately 57% of the U.S. population, while more than 10 additional states have pending legislation. Michigan and Maryland recently added requirements, creating a multiyear adoption runway. CONMED is also seeing early traction internationally and expects its next-generation PlumeSafe X5 to strengthen penetration in ambulatory and outpatient settings. Biobrace and Orthopedic Soft-Tissue Repair Can Support Sustained Growth: BioBrace is emerging as another differentiated growth franchise, particularly in rotator cuff repair, where approximately 1 million procedures are performed annually in the United States and re-tear rates remain significant. CONMED cites a 94% healing rate among high-risk patients using BioBrace augmentation, supported by more than 30 published studies and updated AAOS guidelines recommending augmentation. The one-year-old BioBrace RC product is also gaining traction because it simplifies and standardizes augmentation, encouraging repeat utilization. Management noted increasing new-user adoption and durable retention among surgeons who gain experience with the product. These dynamics could create a recurring growth engine as BioBrace penetrates a large unmet clinical need. Challenges Facing CNMD StockAirSeal Growth Is Moderating Relative to Earlier Expectations: Although AirSeal remained the top contributor to General Surgery growth in the second quarter, its performance was below management's expectations. The company now expects growth to improve in the second half of 2026, but at a slower pace than previously anticipated, prompting a more measured outlook. This matters because AirSeal is a key component of CONMED's growth thesis, and a slower adoption curve could delay the benefits expected from robotic surgery, laparoscopic procedures and ASC expansion. Management continues to believe the franchise can generate high-single-digit to low-double-digit long-term growth, but the near-term deceleration highlights execution and adoption risks even within one of the company's highest-priority growth platforms. Tariffs Remain a Meaningful Earnings Headwind Despite Refund: CONMED’s second-quarter EPS benefited materially from a 21-cent-per-share tariff refund, creating a risk that investors may overestimate the sustainability of the quarter’s earnings strength. Management noted that the refund was related to tariffs paid in 2025, while the company continues to expect a roughly 35-cent-per-share EPS headwind from tariffs in 2026. Excluding the refund, second-quarter adjusted operating margin was essentially flat year over year, underscoring that underlying profitability was less robust than the headline 250-basis-point margin expansion suggested. As a result, future earnings growth will need to be driven by organic sales growth, product mix, and operating efficiencies instead of temporary tariff benefits. Estimate TrendCONMED is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has improved 3.7% to $4.54 per share. The Zacks Consensus Estimate for third-quarter 2026 revenues and EPS is pegged at $336.8 million and $1.00, respectively, suggesting a decline of 0.3% and 7.4% from the year-ago reported numbers. Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) . Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here. GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%. West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%. WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%. The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%. COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
	Saved 2026-07-31 13:37 1mo ago Published 2026-07-31 03:51 1mo ago	Arrowstreet zvýšil podíl v CONMED, zisk na akcii i tržby překonaly odhady Arrowstreet Capital v 1. čtvrtletí zvýšil podíl v CONMED o 217,6 % na 419 092 akcií po nákupu 287 150 kusů. CONMED zároveň oznámil EPS 1,38 USD a tržby 343,49 milionu USD, obojí nad odhady. CNMD CONMED	FMP Stock News	72
Original source text Posted by Defense World Staff on Jul 31st, 2026 Arrowstreet Capital Limited Partnership lifted its position in shares of CONMED Corporation (NYSE:CNMD – Free Report) by 217.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 419,092 shares of the company’s stock after buying an additional 287,150 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 1.39% of CONMED worth $14,819,000 at the end of the most recent quarter. Several other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC increased its position in CONMED by 19.9% in the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock worth $857,000 after purchasing an additional 2,357 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock worth $1,108,000 after buying an additional 800 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of CONMED by 5.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock worth $4,993,000 after buying an additional 4,565 shares during the last quarter. Intech Investment Management LLC raised its position in shares of CONMED by 34.6% during the 1st quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after buying an additional 5,780 shares in the last quarter. Finally, Creative Planning purchased a new stake in shares of CONMED during the 2nd quarter valued at about $310,000. CONMED Stock Up 8.9% NYSE:CNMD opened at $47.04 on Friday. CONMED Corporation has a twelve month low of $31.44 and a twelve month high of $56.63. The company has a market cap of $1.42 billion, a price-to-earnings ratio of 25.43, a price-to-earnings-growth ratio of 3.20 and a beta of 0.93. The stock has a fifty day simple moving average of $37.09 and a 200-day simple moving average of $38.42. The company has a current ratio of 2.29, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. CONMED (NYSE:CNMD – Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.28. The firm had revenue of $343.49 million during the quarter, compared to analyst estimates of $337.60 million. CONMED had a net margin of 4.12% and a return on equity of 14.38%. The business’s revenue was up .3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.15 earnings per share. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Analysts anticipate that CONMED Corporation will post 4.38 EPS for the current year. Analyst Ratings Changes CNMD has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of CONMED in a research report on Thursday, June 4th. BMO Capital Markets assumed coverage on CONMED in a research report on Wednesday, July 8th. They set a “market perform” rating and a $36.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on CONMED from $43.00 to $40.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a report on Monday, July 13th. Finally, Wall Street Zen raised CONMED from a “hold” rating to a “buy” rating in a research report on Monday, July 20th. Five research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $41.40. Read Our Latest Research Report on CONMED Key Headlines Impacting CONMED Here are the key news stories impacting CONMED this week: Positive Sentiment: Quarterly earnings beat expectations. CONMED reported second-quarter EPS of $1.38, well above the $1.10 consensus estimate and up from $1.15 a year earlier. Revenue reached $343.5 million, surpassing the $337.6 million consensus forecast. CONMED Corporation Reports Second Quarter 2026 Financial Results Positive Sentiment: Full-year EPS guidance was raised above Wall Street expectations. Management now expects 2026 adjusted EPS of $4.48-$4.60, compared with the roughly $4.37 analyst consensus. Margin expansion, solid international sales and 6% organic sales growth excluding discontinued GI product offerings supported the improved outlook. CONMED Q2 Earnings and Revenues Beat Estimates Positive Sentiment: Analysts increased their price targets. Wells Fargo raised its target to $46 from $39, while Piper Sandler increased its target to $45 from $39, reflecting greater confidence following the earnings report. Neutral Sentiment: Reported revenue growth remains limited. Sales increased only 0.3% year over year to $343.5 million, or declined 0.5% on a constant-currency basis, although underlying organic growth was stronger after excluding strategic GI product exits. CONMED Q2 Earnings and Revenues Top Estimates Negative Sentiment: Valuation and analyst ratings could limit further gains. Piper Sandler reaffirmed a “neutral” rating and Wells Fargo maintained “equal weight.” Their $45 and $46 targets are below the stock’s recent trading level, signaling that analysts view much of the earnings optimism as already reflected in CNMD’s valuation. About CONMED (Free Report) CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology. CONMED operates two principal segments: Orthopedics, and Visualization & Energy. Read More Five stocks we like better than CONMED Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEAshton Thomas Securities LLC Purchases 1,411 Shares of Caterpillar Inc. $CAT NEXT HEADLINE »The Allstate Corporation $ALL Shares Acquired by Bank of America Corp DE
	Saved 2026-07-30 01:34 1mo ago Published 2026-07-29 19:26 1mo ago	Conmed ve 2. čtvrtletí překonal odhady zisku na akcii i tržeb Conmed ve 2. čtvrtletí vykázal zisk 1,38 USD na akcii a tržby 343,49 milionu USD, obojí nad odhady. Akcie od začátku roku přidaly asi 9 %. CNMD CONMED	FMP Stock News	78
Original source text Conmed (CNMD - Free Report) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +25.46%. A quarter ago, it was expected that this medical technology company would post earnings of $0.82 per share when it actually produced earnings of $0.89, delivering a surprise of +8.54%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Conmed, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $343.49 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.85%. This compares to year-ago revenues of $342.35 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Conmed shares have added about 9% since the beginning of the year versus the S&P 500's gain of 8.5%. What's Next for Conmed?While Conmed has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Conmed was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.05 on $334.99 million in revenues for the coming quarter and $4.38 on $1.36 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Dentsply International (XRAY - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6. This dental products manufacturer is expected to post quarterly earnings of $0.36 per share in its upcoming report, which represents a year-over-year change of -30.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Dentsply International's revenues are expected to be $883.85 million, down 5.6% from the year-ago quarter.
	Saved 2026-07-23 18:15 1mo ago Published 2026-07-23 13:16 1mo ago	FDA rozšířila AirSeal pro da Vinci 5 FDA rozšířila použití AirSeal od CONMED pro 8mm kanyly Hex na platformě da Vinci 5 od Intuitive Surgical. Řešení je nyní kompatibilní napříč systémy da Vinci X, Xi i 5. CNMD CONMED	FMP Stock News	78
Original source text Key Takeaways CONMED's AirSeal is now FDA-cleared for 8 mm hex cannulas on the da Vinci 5 robotic platform.Joint testing with Intuitive Surgical supported compatibility across da Vinci X, Xi and 5 systems.AirSeal maintains pressure, clears smoke and supports low-pressure insufflation during robotic surgery. CONMED (CNMD - Free Report) recently announced that the FDA has expanded the indication for its AirSeal Robotic Solution to be used with Intuitive Surgical’s (ISRG - Free Report) 8 mm hex cannulas on the da Vinci 5 (dV5) robotic surgery platform. Previously approved for Intuitive Surgical’s 8 mm round cannulas, the solution is now compatible across the full portfolio of the da Vinci X, da Vinci Xi and da Vinci 5 robotic systems. Management noted that the expanded indication was supported by extensive engineering and technical compatibility testing conducted jointly with Intuitive Surgical. The company remains focused on providing surgeons and hospitals with compatibility data and clear product communication, helping them deliver high-quality patient care. The expanded indication brings greater clarity on the integration of the AirSeal Robotic Solution with the da Vinci 5 platform, supporting efficient and consistent surgical workflows while contributing to positive patient outcomes. Management also expressed confidence that this achievement strengthens the long-term growth potential of CONMED’s AirSeal portfolio. Likely Trend of CNMD Stock Following the NewsFollowing the announcement, CNMD shares gained 0.3% at yesterday’s close. Year to date, the stock has risen 3.5% against the industry’s 2.2% decline. However, the S&P 500 has risen 9.3% in the same timeframe. CONMED is well positioned to benefit from the expanded indication for its AirSeal Robotic Solution. Compatibility with the da Vinci 5 platform broadens the product’s addressable market and reinforces its value within robotic-assisted minimally invasive surgeries. As hospitals continue to adopt ISRG’s latest robotic platform and the company continues to expand in international markets, adoption of CONMED’s AirSeal is likely to be strengthened, which will drive growth for its surgical portfolio. CNMD currently has a market capitalization of $1.26 billion. Image Source: Zacks Investment Research More on the NewsThe AirSeal Robotic Solution is an advanced insufflation system developed specifically for robotic-assisted minimally invasive surgery. It combines an AirSeal Cannula Cap with AirSeal and a bifurcated tube set to deliver stable pneumoperitoneum, continuous smoke evacuation and low-pressure insufflation through robotic ports, eliminating the need for an accessory port. Unlike conventional insufflation systems that replenish carbon dioxide only after pressure drops, AirSeal maintains pressure, improving visualization and minimizing interruptions during surgery. Its three-lumen design provides CO2 insufflation, smoke evacuation and a regulated gas barrier that maintains consistent cavity pressure even during leaks or suction. By preserving visualization, minimizing pressure fluctuations and restoring pneumoperitoneum when disruptions occur, the system supports physiologic stability, enhances intraoperative efficiency and contributes to smoother patient recovery during minimally invasive robotic procedures. The expanded indication strengthens AirSeal’s role in robotic surgery by enabling seamless integration with Intuitive Surgical’s latest system architecture while providing hospitals and surgeons with greater flexibility in using complementary technologies. Backed by more than 40 clinical studies, the system is designed to support low-pressure insufflation, helping improve patient outcomes, procedural efficiency and surgical performance. Industry Prospects Favoring the MarketGoing by the data provided by Mordor Intelligence, the insufflation devices market is predicted to be valued at $3.28 billion in 2026 and is expected to witness a CAGR of 5.9% through 2031. Factors like the growing adoption of minimally invasive surgeries, advancements in insufflation technology, rising volumes of bariatric and gynecologic procedures, integration with digital operating rooms, expanding ambulatory surgery infrastructure and a shift toward disposable insufflation consumables are boosting the market’s growth. Other NewsCONMED recently appointed John E. Gallagher as its chief financial officer, effective July 15, 2026. He succeeds Todd Garner, who will remain associated with the company in an advisory role through Nov. 2, 2026. Gallagher brings nearly three decades of financial leadership experience across public healthcare and industrial companies, including Certara, Inc., Cue Health Inc. and Becton, Dickinson & Co. In May, CONMED announced the appointment of seasoned healthcare executives Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026. The move expands the board to nine members and strengthens governance with deep leadership expertise from Johnson & Johnson and Boston Scientific. CNMD’s Zacks Rank & Key PicksCONMED currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. West Pharmaceutical reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%. Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%. Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.